Ronald L. Koretz, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editors: Drs. Toto and colleagues (1) recently described eight patients who had reversible renal insufficiency that was attributed to the use of an angiotensin-converting enzyme inhibitor. They noted that these eight patients were identified during a randomized trial, which was annotated as their reference 9 (2). They further noted that three of the eight cases had been partially reported in their reference 10 (3).
They described the randomized trial: seventy-three patients were treated with various antihypertensive agents and were randomized to receive an angiotensin-converting inhibitor or a placebo. Reference 9, however, appears to report a different randomized trial.
Koretz RL. Studies within Studies. Ann Intern Med. 1992;116:698. doi: 10.7326/0003-4819-116-8-698_1
Download citation file:
Published: Ann Intern Med. 1992;116(8):698.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use